Lake Street analyst Frank Takkinen raised the firm’s price target on Silk Road Medical to $28 from $20 and keeps a Buy rating on the shares after Q4 revenue and 2024 guidance exceeded expectations. While shares have closed some of the valuation gap, the firm continues to believe further upside exists, the analyst tells investors in a post-earnings note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on SILK:
- Silk Road Medical Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Financial Outlook
- SILK Earnings this Week: How Will it Perform?
- Silk Road Medical participates in a conference call hosted by Lake Street
- Silk Road Medical to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
- Silk Road Medical upgraded to Buy from Hold at Stifel
